Pre-incorporation · emerging from King's College London

Engineering the future of oral therapeutics

EVora is building a vesicle-based delivery platform that lets biological medicines be swallowed rather than injected, drawing on both natural extracellular vesicles and synthetic lipid vesicles modelled on them.

Backed by non-dilutive awards from UKRI, Wellcome Leap and Sanofi
The problem

Biologics can't be swallowed

Biological drugs such as insulin break down in the gut and are poorly absorbed. Today, injection is the only option for most of them.

Today: injection only

  • ×
    PainfulA burden that reduces adherence to treatment
  • ×
    ExpensiveOften needs a healthcare professional to administer
  • ×
    Risk of complicationsInjection-site and handling risks
  • ×
    High carbon footprintCold chain, needles, sharps and clinical waste

With oral delivery

  • ✓
    Accessible and convenientEasy to take and acceptable to patients
  • ✓
    Lower treatment costsNo healthcare professional needed to administer
  • ✓
    Rapid mass immunisationOral vaccines for future pandemics
  • ✓
    Lighter footprintSimpler supply, storage and disposal
Our technology

Nature built the oral carrier. We engineer it further.

Extracellular vesicles (EVs) are nanoscale lipid particles that cells use to carry molecular cargo. Some, such as those in milk, evolved to survive digestion and cross the gut. EVora works across two complementary vesicle families to turn that biology into a drug-delivery platform.

Natural

Milk-derived EVs

Vesicles isolated from milk that are naturally adapted to the gastrointestinal tract.

  • Evolved to survive digestion and cross the infant gut
  • Food-grade source, compatible with GRAS status
  • Manufacturable at scale without complex lipid chemistry
+
Bio-inspired

Synthetic EV-inspired lipid vesicles

Engineered lipid vesicles designed using what we learn from natural EVs: their membrane composition, surface features and gut behaviour.

  • Defined, reproducible composition
  • Lipids and ligands chosen to tune stability, targeting and release
  • Stimulus-responsive coatings, such as ROS-triggered release

One design philosophy, two carrier routes. We choose the vesicle that best fits each payload and indication.

01

Protect

Vesicles shield biologics from harsh gastric conditions and digestive enzymes.

02

Target

They cross the mucus layer and interact with the epithelium, enhancing uptake and transport at the gut wall.

03

Cross

They can cross the epithelial barrier to deliver the payload locally or into systemic circulation.

The platform

One platform, tailored to every payload

The same core platform, engineered for each payload and indication.

Vesicle selection

Natural milk EVs or synthetic EV-inspired vesicles

Cargo loading

Biologics loaded into the vesicle

Surface engineering

Lipid and ligand modification tunes stability, targeting and release

Oral dosing

Off-the-shelf capsules, swallowed: no injection needed

Targeted release

Cargo released systemically or at the disease site

One carrier, many payloads
Peptides & proteinsAntibodiesmRNAsiRNAOligonucleotidesSmall moleculesAntibioticsMicronutrientsOther biologics
Proprietary: protected IP plus accumulated engineering know-how in vesicle isolation, loading and surface engineering.
Pipeline

Three programmes, one platform

A lead programme in oral biologics, with two follow-on applications built on the same carrier technology.

Lead programme

EVora Pharma

Oral biologics
  • Peptide and protein biologics, led by insulin and GLP-1 agonist formulations
  • siRNA and mRNA therapeutics
  • An oral alternative to injectable dosing
GoalTurning today's injectable biologics into medicines patients can swallow
Discovery

EVora Anti-Infective

Focused antibiotics for the lung · Wellcome Leap-funded
  • ROS-responsive lipid coating
  • Site-specific release in infected lung tissue
  • Targets bacterial pneumonia and cystic fibrosis
Early feasibility

EVora Nutrition

Iron and micronutrients · potential fast lane
  • Improved oral bioavailability
  • GI-friendly delivery with fewer side effects
  • Targets anaemia and nutritional deficiency
Investors

An early opportunity in oral biologics

EVora is at a pre-incorporation stage, preparing to spin out of King's College London. We are opening conversations with investors who want to help take an oral biologics platform, already validated by competitive non-dilutive funding, towards the clinic.

Pre-incorporation

An early entry point into a platform company with established IP, formulation know-how and three programmes built on one carrier platform.

Company stage: pre-incorporation. The company is being formed; the founders currently hold academic appointments at King's College London.
Stage
Pre-incorporation

Spin-out from King's College London

Validation
3 competitive awards

Non-dilutive funding from UKRI, Wellcome Leap and Sanofi

Lead asset
Oral insulin & GLP-1

Plus siRNA / mRNA formulations

Model
Partner-led platform

Licences, milestones and royalties

Backed by three competitive funders

Non-dilutive funding already validates the platform.

£2.5M
UKRI Engineering Biology Grant

Supports core platform engineering, with a focus on oral RNA delivery.

Multimillion-dollar
Wellcome Leap Award

Backs translational development of microbiome-sparing oral antibiotic delivery.

€0.1M
Sanofi iAward Europe

Industry validation from a global pharmaceutical company.

Platform feasibility validated by three independent, competitive funders
Core IP and formulation know-how established ahead of this raise
Antibiotic programme already in translational development

Large markets, each set to roughly double

Market size in 2025 versus forecast, US$ billions.

2025Forecast
Oral peptides & proteinsforecast 2030
IBD treatment, oral RNAforecast 2033
Oral iron supplementsforecast 2034
~$22B

Oral and systemic antibiotics market (2025), with ~$2–7B potentially replaceable by microbiome-sparing approaches

~2×

Forecast growth in every segment (1.8× to 2.2×) by 2030–2034

Sources: MarketsandMarkets (oral proteins and peptides); Research and Markets (IBD treatment); IMARC (oral antibiotics); Custom Market Insights (iron supplements). Figures as cited in each report.

Multiple routes to value

Three commercial programmes, each with a partner-led model.

ProgrammeWhat we sellWhy partners buyCommercial model
EVora PharmaPeptides, proteins, antibodies, RNA, vaccinesOral delivery platformTurn injectable or poorly absorbed drugs into oral productsResearch collaboration, licence, milestones and royalties
EVora Anti-InfectiveMicrobiota-sparing antibioticsTargeted, microbiota-sparing deliveryImprove targeting and reduce collateral microbiome disruptionCo-development or licence
EVora NutritionPoorly absorbed micronutrients, e.g. iron and zinc
Potential fast lane
Enhanced micronutrient deliveryImprove absorption and potentially reduce dose and GI effectsIngredient licence or B2B partnership

Interested in investing?

We welcome conversations with investors and strategic partners ahead of incorporation. Get in touch with the founders to request the full investor deck.

Contact the founders
Team

Deep drug-delivery expertise

King's College London expertise in drug delivery, nanomedicine and translational science.

DV
Co-founder

Driton Vllasaliu

Expert in oral drug delivery and mucosal biology; leads platform development of vesicle-based oral carriers.

MT
Co-founder

Maya Thanou

Specialist in nanomedicine and targeted drug delivery; drives formulation and ROS-responsive lipid engineering.

Co-founders hold academic appointments at King's College London.

Get in touch

Let's make biologics swallowable

For investment, partnership or research collaboration enquiries, please contact Driton Vllasaliu or Maya Thanou at King's College London.